CN111983240A - Visual detection method for clostridium perfringens alpha toxin - Google Patents
Visual detection method for clostridium perfringens alpha toxin Download PDFInfo
- Publication number
- CN111983240A CN111983240A CN202010883292.3A CN202010883292A CN111983240A CN 111983240 A CN111983240 A CN 111983240A CN 202010883292 A CN202010883292 A CN 202010883292A CN 111983240 A CN111983240 A CN 111983240A
- Authority
- CN
- China
- Prior art keywords
- cpa
- antibody
- alpha toxin
- detection
- clostridium perfringens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010081427 Clostridium perfringens alpha toxin Proteins 0.000 title claims abstract description 75
- 238000001514 detection method Methods 0.000 title claims abstract description 55
- 230000000007 visual effect Effects 0.000 title claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 43
- 239000004005 microsphere Substances 0.000 claims abstract description 23
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 17
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 238000001917 fluorescence detection Methods 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 10
- 238000010168 coupling process Methods 0.000 claims abstract description 10
- 238000005859 coupling reaction Methods 0.000 claims abstract description 10
- 238000012545 processing Methods 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 5
- 238000002474 experimental method Methods 0.000 claims description 24
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 23
- 101710197219 Alpha-toxin Proteins 0.000 claims description 23
- 101710124951 Phospholipase C Proteins 0.000 claims description 23
- 239000002776 alpha toxin Substances 0.000 claims description 23
- 241000193468 Clostridium perfringens Species 0.000 claims description 20
- 238000010790 dilution Methods 0.000 claims description 18
- 239000012895 dilution Substances 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000007062 hydrolysis Effects 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000000903 blocking effect Effects 0.000 claims description 7
- 238000010276 construction Methods 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 7
- 230000001988 toxicity Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 102220362486 c.167A>G Human genes 0.000 claims description 5
- 231100000225 lethality Toxicity 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000012935 Averaging Methods 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 231100001102 clostridial toxin Toxicity 0.000 abstract description 4
- 238000011897 real-time detection Methods 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 27
- 239000003053 toxin Substances 0.000 description 25
- 231100000765 toxin Toxicity 0.000 description 25
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 238000002073 fluorescence micrograph Methods 0.000 description 6
- 101710146739 Enterotoxin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000147 enterotoxin Substances 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 101710139849 Alpha-toxin 4 Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- -1 carboxyl modified silicon dioxide Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 1
- DKQCWCQRAMAFLN-UBHSHLNASA-N Asp-Trp-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O DKQCWCQRAMAFLN-UBHSHLNASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- SXIJQMBEVYWAQT-GUBZILKMSA-N Gln-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXIJQMBEVYWAQT-GUBZILKMSA-N 0.000 description 1
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 1
- HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 1
- LJLPOZGRPLORTF-CIUDSAMLSA-N Glu-Asn-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LJLPOZGRPLORTF-CIUDSAMLSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- DAHLWSFUXOHMIA-FXQIFTODSA-N Glu-Ser-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O DAHLWSFUXOHMIA-FXQIFTODSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- LGQZOQRDEUIZJY-YUMQZZPRSA-N Gly-Cys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CS)NC(=O)CN)C(O)=O LGQZOQRDEUIZJY-YUMQZZPRSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- MBSSHYPAEHPSGY-LSJOCFKGSA-N His-Ala-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O MBSSHYPAEHPSGY-LSJOCFKGSA-N 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- CTEMYIWDSVICKS-WDSOQIARSA-N His-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N CTEMYIWDSVICKS-WDSOQIARSA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- DGAAQRAUOFHBFJ-CIUDSAMLSA-N Lys-Asn-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DGAAQRAUOFHBFJ-CIUDSAMLSA-N 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- GRADYHMSAUIKPS-DCAQKATOSA-N Lys-Glu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRADYHMSAUIKPS-DCAQKATOSA-N 0.000 description 1
- LHXFNWBNRBWMNV-DCAQKATOSA-N Met-Ser-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LHXFNWBNRBWMNV-DCAQKATOSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- JLDZQPPLTJTJLE-IHPCNDPISA-N Phe-Trp-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JLDZQPPLTJTJLE-IHPCNDPISA-N 0.000 description 1
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 1
- LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
- UQGAAZXSCGWMFU-UBHSHLNASA-N Ser-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N UQGAAZXSCGWMFU-UBHSHLNASA-N 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- DIHPMRTXPYMDJZ-KAOXEZKKSA-N Thr-Tyr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N)O DIHPMRTXPYMDJZ-KAOXEZKKSA-N 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- OSMTVLSRTQDWHJ-JBACZVJFSA-N Tyr-Glu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 OSMTVLSRTQDWHJ-JBACZVJFSA-N 0.000 description 1
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 description 1
- GYKDRHDMGQUZPU-MGHWNKPDSA-N Tyr-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GYKDRHDMGQUZPU-MGHWNKPDSA-N 0.000 description 1
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
- QPOUERMDWKKZEG-HJPIBITLSA-N Tyr-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QPOUERMDWKKZEG-HJPIBITLSA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 101150085553 cpb-2 gene Proteins 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010029599 tyrosyl-glutamyl-tryptophan Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a visual detection method for clostridium perfringens alpha toxin, which combines an intelligent mobile phone image processing technology and silica microsphere antibody coupling to detect food-borne clostridium perfringens alpha toxin (CPA). According to a double-antibody sandwich principle, the prepared CPA polyclonal antibody is coupled with a silicon dioxide microsphere, CPA fluorescence detection is carried out through FITC fluorescence labeled by the antibody, and finally real-time detection of CPA content is realized by combining with an image processing technology of an intelligent mobile phone APP. Compared with the traditional detection method of clostridial toxin, the nano-microsphere combined with the intelligent mobile phone CPA detection system is a more sensitive, stable and convenient detection method, and a new method is provided for detecting natural CPA in food.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a detection method of a food-borne pathogenic bacterium, namely clostridium perfringens alpha toxin.
Background
Clostridium perfringens (Clostridium perfringens), also known as food-borne gastroenteritis and other infectious diseases. As a opportunistic pathogen, it can contaminate many types of retail meat products and produce alpha toxin in the small intestine of livestock[1]Food poisoning may result when milk and dairy products contaminated with such bacteria or toxins are consumed. Clostridium perfringens causes a variety of diseases in a variety of hosts due to the production of a variety of toxins and extracellular enzymes[2]. To date, at least 20 exotoxins have been discovered, with the major lethal toxins being α, β, and iota. Because all types of toxins can produce alpha toxin and cause hemorrhagic enteritis and acute death in livestock[3]And alpha toxin is the most important virulence factor of clostridium perfringens type a[4]. It has cytotoxicity, hemolytic activity, lethality, skin necrosis, and muscle necrosis[5]Production of granulocytes[6]Inhibition of erythroid differentiation[7]Platelet aggregation and increased vascular permeability.
Currently, the detection of clostridium perfringens is mainly based on molecular biological examination PCR or immunological examination ELISA and the like. Oisvik et al established a four-layer sandwich method for the detection of Clostridium perfringens enterotoxin. This method can detect enterotoxin at 0.1. mu.g/mL, but the entire experiment takes 4 days to complete. McClane et al[8]The established indirect ELISA method can detect enterotoxin with the concentration of 25ng/mL and shorten the experimental time. Hale et al[9]An antigen capture ELISA method is established for detecting the clostridium perfringens toxin, the method has good specificity and sensitivity, and the minimum detection amount of alpha toxin is 19 ng/mL. These methods can be used to diagnose Clostridium perfringens using PCR techniques instead of serum neutralization assays[10]The goat feces and the toxin content of the gastrointestinal tract were successfully tested.In 1997, a PCR technique was established to determine four different toxins in goat feces. However, the method established by Uzal is cumbersome and uneconomical and the sample needs to be tested four times. Yoo et al[11]Multiplex PCR was established to detect the four major toxins of clostridium perfringens, but this approach requires extraction and purification of the bacterial genome. Baums CG, etc[12]A multiplex PCR method capable of typing Clostridium perfringens is established, which can directly detect and distinguish cpa (alpha), cpb (beta 1), etx (), iap (iota), cpe (enterotoxin) and cpb2 (beta 2) and other toxin genes, and has good specificity and repeatability. Furthermore, Gurjar et al[13]Fluorescent quantitative PCR was established. The major toxin gene of clostridium perfringens can be detected directly from fecal samples and can be used for epidemiological investigation of diseases. In conclusion, the sensitivity of detecting clostridium perfringens by ELISA in the prior art is higher, and the lowest detection limit can reach 19ng/mL, but the general problem is that the operation process is time-consuming and tedious; and a PCR method can be used for simultaneously detecting various clostridium perfringens toxins, but the toxins need to be purified in the detection process, the sensitivity is not high, and the method is time-consuming and tedious. Therefore, it is necessary to establish a detection system for detecting clostridial toxins that is efficient, sensitive, and convenient.
Disclosure of Invention
The invention aims to provide a visual detection method for clostridium perfringens alpha toxin, which is used for solving the problems of low detection limit, long time, single detection technology deficiency and the like in the prior art.
The purpose of the invention is realized by the following technical scheme:
a visual detection method for rapidly detecting food-borne clostridium perfringens alpha toxin in real time based on combination of silica microspheres and a smart phone comprises the steps of injecting CPA truncated protein expressed by pronucleus into an animal to prepare an antibody, labeling the antibody with Fluorescein Isothiocyanate (FITC), coupling the silica microspheres to capture the alpha toxin in food, uploading a detected fluorescence image to a mobile phone APP, and immediately obtaining the concentration of the alpha toxin in a sample to be detected in real time.
The prokaryotic expression CPA protein truncation CPANThe construction of (2) and the preparation of antibodies comprising two mutation sites of CPA protein (D56G, D130G), the CPANThe protein sequence of truncated body SEQ ID No. 1.
The method comprises the following main steps:
(1) CPA protein truncation CPANThe construction of (1): because of the toxicity and lethality of CPA proteins, the use of CPA mutants in experiments to eliminate the toxic effects on immunized animals is convenient for subsequent antiserum preparations. Plasmid containing mutant of amino acid at position 4 (pET30 a-CPA) given by professor of the aged cloudm4) And a C-terminal triple-copy tandem plasmid (pET30 a-CPA)C3)[14,15]. At CPAm4Design of primers (CPA)m4Del TM-F, SEQ ID No.2 and CPAm4Dele TM-R, SEQ ID No.3) deletion transmembrane domain to obtain N-terminal truncated plasmid pET30a-CPANThe plasmid contained only two amino acid mutations (D56G, D130G).
(2) Preparing an antibody: the constructed pET30a-CPANAnd pET30a-CPA for benefit of professorC3Prokaryotic expression vector is transformed into competent cell of Escherichia coli BL21(DE3), and recombinant protein is induced and purified by IPTG. anti-CPA was obtained by immunizing rabbits three times with a protein amount of 1mg/mLC3And CPANThe polyclonal antibody is purified by rabbit serum and a Saturated Ammonium Sulfate (SAS) precipitation method, and the antibody titer is detected by Western-blot and ELISA.
(3) CPA Using semi-permeable Membrane methodNThe labeling of Fluorescein Isothiocyanate (FITC) of the antibody is convenient for the coupling and fluorescence detection of the subsequent silica microspheres, the general principle of the detection is shown in fig. 7, and the fluorescence intensity of the microspheres detected by a fluorescence microscope is the concentration of the corresponding clostridial alpha toxin by utilizing the antigen-antibody combined double antibody sandwich principle.
The CPA protein truncated body silica microsphere coupling comprises the following steps:
(1) the toxicity substitution experiment, namely the lecithin hydrolysis experiment, is used for quantifying the clostridium perfringens alpha toxin, and the finally measured natural CPA concentration is 10LD50。
(2) Silica microspheresActivation of (2): CPA coupled with surface of carboxylated silicon dioxide microsphereNPolyclonal antibody, adding coupling agent N-hydroxysuccinimide (NHS) and carbodiimide (EDC) with final concentration of 10mg/mL, and finally blocking.
(3) Optimizing the conditions of the silica microsphere detection experiment: the optimal conditions for the fluorescence detection experiment were determined from the experimental data, namely capture antibody (CPA) at 0.1mg/ml at 25 deg.CC3) After 2h interaction with activated silica microspheres, blocking was performed with 5% BSA overnight at 4 deg.C, the next day at 37 deg.C, alpha toxin and 0.2mg/ml detection antibody (FITC-CPA)N) And (3) interacting with the silica microspheres coupled with the capture antibody for 1h, and detecting by a fluorescence microscope.
Establishment of alpha toxin capture standard curve, detection line sensitivity is 0.625LD50The detection time is about 90 min.
The method comprises the following steps:
(1) establishment of a standard curve: and carrying out double gradient dilution on natural clostridium perfringens alpha toxin (CPA) for 5 dilutions, wherein each dilution is 3 biological replicates, and then detecting the fluorescence intensity of the silica microspheres coupled with the FITC labeled antibody to obtain a group of fluorescence pictures.
(2) The fluorescence intensity in the picture is subjected to gray value analysis (conventional image analysis software such as Photoshop and ImageJ is used), the research uses the ImageJ software to perform gray value analysis, firstly, the picture is converted into an 8-bit gray value picture, background interference is eliminated, then, brightness values in all image areas are selected to perform averaging analysis, finally, the average gray value of a corresponding image is obtained, and data are sorted to obtain a regression equation Y which is 0.01915X +0.002875 (R)20.9972). Wherein X represents LD50And Y represents an average gray value.
(3) The image processing technology is programmed into an intelligent mobile phone APP, the general principle is that RGB value analysis is carried out on a picture, then RGB color values are converted into hexadecimal color codes (gray), accordingly the gray value of the picture is obtained, and finally different gray value ranges correspond to CPA concentrations through an IF algorithm. After the APP is prepared, the corresponding CPA concentration can be directly obtained by uploading a fluorescence picture.
Based on the method, the invention provides a method for detecting clostridium perfringens alpha toxin in real time by combining the silica microspheres with a smart phone.
The invention has the beneficial effects that: the invention discloses a method for detecting food-borne clostridium perfringens alpha toxin by coupling alpha toxin antibody with FITC label and silica microspheres according to a double-antibody sandwich method. And analyzing and processing the fluorescence micrographs through APP software universal for android smart phones to determine the content of the alpha toxin. The lowest detection limit of the method is 0.625LD50And the whole detection time is less than or equal to 90 min. The whole data processing time is less than 5 seconds. The method has the advantages of good stability, high sensitivity, convenience and rapidness in operation and the like, and provides a new idea and direction for detecting the food-borne clostridium perfringens alpha toxin.
Drawings
FIG. 1: CPA recombinant protein CPAC3And CPANSDS-PAGE results of expression and purification; (a) CPAC3Expression electrophoretogram of recombinant protein. Lanes 1-2 are purified CPA C32 samples of recombinant protein; (b) CPANElectrophoresis result of recombinant protein M: protein molecular mass Standard (Blue Plus) lanes 3-4 are purified CPANTwo parallel samples of recombinant protein;
FIG. 2: clostridium perfringens alpha toxin (CPA)C3And CPAN) (iii) determination of polyclonal antibody concentration and titer;
(a) standard curve of antibody concentration by Bradford method;
(b) recombinant protein CPAC3Western blot results of (M: protein marker (GenStar M221) lanes 1-2: CPA)C3Recombinant proteins);
(c) recombinant protein CPAC3And CPANWestern blot results of (M: protein marker (GenStar M221) lanes 3-4: CPA)NRecombinant proteins);
(d) recombinant protein CPAC3Indirect ELISA results of (1): detected CPAC3The titer of the antibody was 1: 3200;
(e) recombinant protein CPANIndirect ELISA results of (1): detected CPANThe titer of the antibody was 1: 6400;
FIG. 3: degree of hydrolysis of CPA by lecithin hydrolysis;
FIG. 4: optimal conditions of a silica microsphere fluorescence detection experiment;
(a) determining the optimal antibody coating conditions (fixing other conditions, selecting toxin concentration as 10LD50, antibody dilution concentration as 0.02, 0.1, 0.5mg/ml, experiment temperature and time as 37 ℃ for 2h, 25 ℃ for 2h, 4 ℃ for 12h, and 3 biological repetitions of each group of experiments);
(b) determining the optimal blocking conditions (fixing other conditions, selecting toxin concentration as 10LD50, selecting blocking agent as 5% milk and 5% BSA, selecting experiment temperature and time as 37 deg.C for 2h, 25 deg.C for 2h, 4 deg.C for 12h, and 3 biological repetitions per group);
(c) the optimal incubation time and the dilution (fixation) of the enzyme-labeled antibody are unchanged, the toxin concentration is 10LD50, the dilution concentration of the fluorescence-labeled antibody is 0.05, 0.1 and 0.2mg/mL, and the experimental temperature and time are respectively 0.5h at 37 ℃, 1h at 37 ℃ and 2h at 37 ℃; 3 biological replicates per set of experiments);
FIG. 5: CPA detected fluorescence map and established standard regression equation;
(a) fluorescence pictures at different toxin concentrations: from left to right, the concentration is respectively 10LD50,5LD50,2.5LD50, 1.25LD50,0.625LD50Three biological replicates per concentration gradient (i.e., corresponding to three columns in the figure);
(b) standard regression equation established based on fluorescence intensity and toxin concentration, Y0.01915X +0.002875 (R)2=0.9972)。
FIG. 6: an APP detection interface of the smart phone;
FIG. 7: principle of silica microsphere coupling fluorescent antibody combined with smartphone APP detection system.
Detailed Description
The invention is further illustrated with reference to the figures and the specific embodiments.
Example 1 basic preparation of the detection method
Step one, the A-type standard strain (C57-1) is purchased from a Chinese veterinary drug inspection institute. Alpha toxin 4 amino acid mutant plasmid (CPA)m4) And in alpha toxin (CPA)C3) The C-terminal three-copy tandem prokaryotic expression vector (pET30a) was constructed by professor cloud Cheng of the Chinese veterinary drug research institute[14,15]。
Because site-directed mutagenesis of toxins can greatly reduce the toxicity and lethality of CPA, subsequent preparation of rabbit serum antibodies without lethality is facilitated.
We then used the existing alpha toxin 4 amino acid mutant plasmid (CPA)m4) The N-terminal truncation construction was performed, and thus the constructed expression vector contained two mutation sites (D56G, D130G). Construction of N-terminal expression vector of CPA PET30a-CPA Using two primersNAccording to Genbank, the alpha toxin gene of clostridium perfringens (Genbank accession number: DQ202275) is searched, and N-terminal truncation body primers (CPA) are designed by removing the transmembrane domainm4Del TM-F, SEQ ID No.2 and CPAm4Del TM-R, SEQ ID No.3), upstream and downstream containing BamHI and Xho I restriction sites, respectively.
Step two, constructing a prokaryotic expression vector (CPA)C3And CPAN) Expressing and purifying prokaryotic recombinant protein, and immunizing rabbit with 1mg/ml protein amount for three times to obtain anti-CPAC3And CPANThe polyclonal antibody is purified by rabbit serum and a Saturated Ammonium Sulfate (SAS) precipitation method, and the antibody titer is detected by Western-blot and ELISA. The results are shown in FIG. 1, where CPA is a recombinant protein CPAC3And CPANCan be expressed normally. As can be seen from FIG. 2, CPA of Clostridium perfringens alpha toxin was determined by Bradford methodC3And CPANThe polyclonal antibody concentration of (2) was 7.02mg/mL and 7.47mg/mL, respectively. Western blot results of FIGS. 2-b, c show that the recombinant protein CPAC3And CPANHas good specificity; FIG. 2-d, e Indirect ELISA test results show that the recombinant protein CPAC3And CPANThe potency of (A) was 1:3200 and 1:6400, respectively.
Step three, CPA is carried out by using a semipermeable membrane methodNLabeling of Fluorescein Isothiocyanate (FITC) of the antibody was performed using a 0.025M carbonate buffer, pH 9.0The wash corrected the protein concentration of the antibody solution to 10mg/mL and placed in the dialysis bag. Simultaneously weighing the amount of the antibody protein 1/20FITC, namely the required amount (mg) of FITC (Beijing Solel technologies, Inc.) is equal to the protein content (mg/mL) multiplied by the amount of the antibody solution (mL) multiplied by 1/20; dissolving FITC in 10 times of 0.025M antibody solution, pH 9.0 carbon in saline buffer, and stirring gently to avoid air bubbles; the antibodies in the dialysis bag were immersed in FITC solution and left at 4 ℃ for 16-18 hours with periodic stirring 1-2 times per hour with a magnetic stirrer for a total stirring time of about 6 hours. The dialysis bag was removed and dialyzed against 0.01M PBS pH7.2 for 4 hours.
And step four, quantifying the clostridium perfringens alpha toxin by using a virulence replacement experiment, namely a lecithin hydrolysis experiment. First, freshly cooked egg yolk is mashed and mixed, then 1% CaCl is added2Physiological saline 40 mg/g and 6% Al (OH)3Gel 3ml/g, mix and place in a refrigerator at 4 ℃ overnight. The following day, the supernatant was collected as lecithin after centrifugation at 720g for 20 minutes. With physiological saline (2)0、2-1、2-2、 2-3、2-4、2-5) The alpha toxin was diluted, 1mL of lecithin was added for each dilution, and then allowed to stand 1 time at 37 ℃. And (4) hours. Negative medium and 1mL lecithin as controls at OD550The absorbance (turbidity) was measured, and the dilution of each hydrolysis reaction was equivalent to 1/6.4LD50Toxicity, i.e. the toxicity of the reaction after 2-fold dilution 2x/6.4 LD50. The final measured native CPA concentration was 10LD50. The results are shown in figure 3, the hydrolysis method of lecithin is used for measuring the hydrolysis degree of CPA, each concentration gradient is subjected to three biological repetitions, a series of light absorption values are obtained, the toxicity and the hydrolysis turbidity degree have stable correlation, the corresponding relation between the hydrolysis degree and the concentration of CPA is calibrated by a curve, and finally CPA with the lowest detectable dilution factor is compared with formula 2x/6.4 LD by the comparison50The clostridial toxin (undiluted) extracted in this experiment was calculated to be 10LD50。
Coupling the carboxyl modified silicon dioxide microspheres with the fluorescent antibody: weighing a certain amount of silica microspheres (particle size 10 μm, Tianjin Yijia science and technology Co., Ltd.) in a ratio of 0.5: 1 EDC was added in a ratio of 1: NHS was added at ratio 1, mixed well and shaken well at room temperature. After 20 minutes, the cells were washed with PBS and centrifuged to remove the washing solution (repeated three times). The optimal experimental conditions for coupling the antibody to the silica microspheres were then determined.
Example 2: condition optimization of detection methods
Step one, determining an optimal coating condition: the variable is the coating antibody (bound silica microsphere antibody CPA)C3) At a concentration of 10LD, under fixed conditions, and at a time and temperature, the toxin concentration is selected to be50(each condition was repeated 3 times) and then the fluorescence image was observed by fluorescence microscope observation, and finally the ratio was obtained by gray value analysis. Finally, the optimal coating conditions were determined to be 0.1mg/mL capture antibody and the silica microspheres were mixed for 2 hours at 25 ℃. The results are shown in figure 4: optimal conditions for microsphere fluorescence detection experiments; (a) determining the optimal antibody coating condition.
Step two, determining the optimal sealing condition: the variables were selected blocking agents (5% skim milk powder or 5% BSA), other conditions were fixed, and the selected toxin concentration was 10LD50(3 replicates per condition) and the grey values of the fluorescence picture analysis were obtained. Finally, the optimal sealing conditions were determined to be 5% BSA at 4 ℃ for 12 hours. The results are shown in figure 4: optimal conditions for microsphere fluorescence detection experiments; (b) the optimal sealing conditions are determined.
Step three, determining the optimal incubation time and the optimal enzyme labeled antibody (CPA)N) Dilution of (c): the variables are the dilution factor (1: 50, 1: 100, 1: 200) and time of the enzyme-labeled antibody and the temperature is fixed, and when other conditions are fixed, the selected toxin concentration is 10LD50(3 biological replicates per condition) and the grey values of the fluorescence images were analyzed. Finally, the enzyme-labeled antibody was optimally diluted at a concentration of 1:50 and the silica microspheres were allowed to act at 37 ℃ for 1 hour. The results are shown in FIG. 4, and the optimal conditions for microsphere fluorescence detection experiment are that the capture antibody (CPA) is 0.1mg/ml at 25 deg.CC3) After 2h interaction with activated silica microspheres, blocking with 5% BSA overnight at 4 deg.C the following dayAlpha toxin and 0.2mg/ml detection antibody (FITC-CPA) were added at 37 deg.CN) And (3) interacting with the silica microspheres coupled with the capture antibody for 1h, and detecting by a fluorescence microscope.
Example 3: establishment of detection method
Step one, performing concentration gradient dilution of toxin CPA, and preliminarily quantitatively determining that the undiluted protoxin concentration is 10LD50Then we serially diluted it 2 times, i.e. 10LD was obtained50,5LD50, 2.5LD50,1.25LD50,0.625LD 503 biological replicates were performed for each concentration gradient and the corresponding fluorescence pictures were obtained by fluorescence microscopy. The results are shown in FIG. 5, and CPA was diluted by 10LD gradient50,5LD50,2.5LD50,1.25LD50,0.625LD50Fluorescence intensity was then measured, and three biological replicates were set up for each concentration gradient. The equation stability is proved to be good.
Step two, using ImageJ software to analyze the gray value, and finally drawing the obtained gray value into a regression curve, wherein the regression equation is as follows: Y0.01915X +0.002875 (R)20.9972). The method is adopted to determine the mouse LD with the minimum detection limit of 0.625 times of the clostridium perfringens alpha toxin50And has high sensitivity. The specific result is shown in figure 5 in the specification.
And step three, dividing five dilutions of the detected toxin into five groups, performing three biological repetitions on each dilution, and analyzing the variation coefficient of the gray value result obtained by detection. The analysis shows that the results are all lower than 15%, which indicates that the variation degree of the same sample in the same batch is low, and the established fluorescent silica microsphere toxin detection method has good stability. The specific results are shown in the specification and attached table 1.
TABLE 1 repeatability test for fluorescence detection of silica microspheres (n ═ 3)
Example 4: silicon dioxide microsphere detection of CPA concentration in food
The effect of the detection technology established in the experiment is evaluated by carrying out actual detection on the milk which is determined according to the GB 4789.13-2012 detection and does not contain the clostridium welchii, namely, the applicability and the interference resistance of the detection system to actual food are tested. For milk, we took low, medium and high concentration (0.625 LD) of clostridium perfringens toxin respectively50, 2.5LD50,10LD50) And mixing them with 1mL of milk, respectively, and then mixing the mixture with the antibody CPAC3With the well-linked fluorescent FITC antibody CPANThe silica microspheres interact for one hour, milk is removed by washing, then the silica microsphere fluorescence detection experiment introduced by us is carried out, the obtained fluorescence image is uploaded to APP, the fluorescence intensity of the APP is analyzed, the corresponding toxin concentration is obtained by conversion according to a standard regression equation, the recovery rate is satisfactory, and the range is 80% -108.8%. The specific results are shown in the specification and attached table 2.
TABLE 2 recovery of different alpha toxin concentrations in milk samples
Example 5: combination of detection method and smart phone
By means of combination of an image processing technology and a smart phone, mobile phone APP application software is further manufactured through programming, and the software program is suitable for all android smart phones. The method comprises the following steps of setting basic parameters: image name, mean gray value and LD50The value is obtained. The specific operation is that the corresponding clostridial toxin concentration is obtained in real time immediately after a fluorescence image obtained by detection is uploaded to a mobile phone APP. The specific result is shown in figure 6 in the specification.
In summary, in the developed system, the whole process is less than 90 minutes, and the detection limit is 0.625LD50And (4) CPA. The result shows that the silicon dioxide microsphere is combined with the CPA detection system of the smart phone, so that the method is sensitive, stable and convenient, and a new method is provided for detecting the natural CPA in the food.
Although the method and the preparation technology of the present invention have been described by way of preferred embodiments, it is obvious to those skilled in the art that the method and the preparation technology described herein can be modified or recombined to realize the final preparation technology without departing from the content, spirit and scope of the present invention. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and content of the invention.
Reference to the literature
1.Jang,Y.S.,et al.,Prevalence,toxin-typing,and antimicrobial susceptibility of Clostridium perfringens from retail meats in Seoul,Korea.Anaerobe,2020:p.102235.
2.Lacey,J.A.,et al.,In silico Identification of Novel Toxin Homologs and Associated Mobile Genetic Elements in Clostridium perfringens.Pathogens,2019.8(1).
3.Kumar,N.P.,N.V.Kumar,and A.Karthik,Molecular detection and characterization of Clostridium perfringens toxin genes causing necrotic enteritis in broiler chickens.Tropical Animal Health and Production,2019.51(9–10).
4.Oda,M.,et al.,Effect of erythromycin on biological activities induced by clostridium perfringens alpha-toxin.J Pharmacol Exp Ther,2008.327(3):p.934-40.
5.Takehara,M.,et al.,Granulocyte Colony-Stimulating Factor Does Not Influence Clostridium Perfringens alpha-Toxin-Induced Myonecrosis in Mice.Toxins(Basel),2019.11(9).
6.Takehara,M.,et al.,Clostridium perfringens alpha-toxin impairs granulocyte colony-stimulating factor receptor-mediated granulocyte production while triggering septic shock.Commun Biol,2019.2:p.45.
7.Takagishi,T.,et al.,Clostridium perfringens alpha-toxin impairs erythropoiesis by inhibition of erythroid differentiation.Sci Rep,2017.7(1):p.5217.
8.<Rapid Detection of Clostridium perfringens Type A Enterotoxin by Enzyme-Linked Immunosorbent Assay.pdf>.
9.<Detection of Clostridium perfringens alpha toxin using a capture antibody ELISA.pdf>.
10.<ENTEROTOXAEMIA IN GOATS.pdf>.
11.<Molecular Typing and Epidemiological Survey of Prevalence of Clostridium perfringens Types by Multiplex PCR.pdf>.
12.Baums,C.G.,et al.,Diagnostic multiplex PCR for toxin genotyping of Clostridium perfringens isolates.Veterinary Microbiology,2004.100(1-2):p.11-16.
13.Gurjar,A.A.,et al.,Real-time multiplex PCR assay for rapid detection and toxintyping of Clostridium perfringens toxin producing strains in feces of dairy cattle.Mol Cell Probes,2008. 22(2):p.90-5.
14. Dugege, et al, evaluation of the expression and immunoprotection of Clostridium perfringens alpha toxin mutants Chinese veterinary bulletin 2019.039(002): p.265-270,280.
15.Jige,D.,et al.,Three Copies Recombinant Expression and Immunogenicity Analysis of C-terminal of Clostridium perfringensαToxin.china animal husbandry&veterinary medicine, 2018。
Sequence listing
<110> Tianjin university
<120> method for visually detecting alpha toxin of clostridium perfringens
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 247
<212> PRT
<213> Artificial sequence ()
<400> 1
His Met Trp Asp Gly Lys Ile Asp Gly Thr Gly Thr His Ala Met Ile
1 5 10 15
Val Thr Gln Gly Val Ser Ile Leu Glu Asn Asp Leu Ser Lys Asn Glu
20 25 30
Pro Glu Ser Val Arg Lys Asn Leu Glu Ile Leu Lys Glu Asn Met His
35 40 45
Glu Leu Gln Leu Gly Ser Thr Tyr Pro Gly Tyr Asp Lys Asn Ala Tyr
50 55 60
Asp Leu Tyr Gln Asp His Phe Trp Asp Pro Asp Thr Asp Asn Asn Phe
65 70 75 80
Ser Lys Asp Asn Ser Trp Tyr Leu Ala Tyr Ser Ile Pro Asp Thr Gly
85 90 95
Glu Ser Gln Ile Arg Lys Phe Ser Ala Leu Ala Arg Tyr Glu Trp Gln
100 105 110
Arg Gly Asn Tyr Lys Gln Ala Thr Phe Tyr Leu Gly Glu Ala Met His
115 120 125
Tyr Phe Gly Gly Ile Asp Thr Pro Tyr His Pro Ala Asn Val Thr Ala
130 135 140
Val Asp Ser Ala Gly His Val Lys Phe Glu Thr Phe Ala Glu Glu Arg
145 150 155 160
Lys Glu Gln Tyr Lys Ile Asn Thr Ala Gly Cys Lys Thr Asn Glu Asp
165 170 175
Phe Tyr Ala Asp Ile Leu Lys Asn Lys Asp Phe Asn Ala Trp Ser Lys
180 185 190
Glu Tyr Ala Arg Gly Phe Ala Lys Thr Gly Lys Ser Ile Tyr Tyr Ser
195 200 205
His Ala Ser Met Ser His Ser Trp Asp Asp Trp Asp Tyr Ala Ala Lys
210 215 220
Val Thr Leu Ala Asn Ser Gln Lys Gly Thr Ala Gly Tyr Ile Tyr Arg
225 230 235 240
Phe Leu His Asp Val Ser Glu
245
<210> 2
<211> 27
<212> DNA
<213> CPAm4
<400> 2
ggatcccata tgtggggggg ggggagg 27
<210> 3
<211> 26
<212> DNA
<213> CPAm4
<400> 3
ctcgagggat gggtcattac cctcgc 26
Claims (6)
1. A visual detection method for clostridium perfringens alpha toxin is characterized in that CPA truncation protein expressed by pronucleus is injected into animals to prepare antibodies, the antibodies are labeled with fluorescein isothiocyanate and then are coupled with silica microspheres to capture the alpha toxin in food, and the concentration of the alpha toxin of a sample to be detected is obtained in real time after a detected fluorescence picture is uploaded to a mobile phone APP.
2. The method for visual detection of clostridium perfringens alpha toxin according to claim 1, wherein said prokaryotic expression CPA protein truncation CPANThe construction of (2) and the preparation of antibodies comprising two mutation sites of CPA protein (D56G, D130G), the CPANThe truncated body is the protein sequence of SEQ ID No. 1.
3. The method for visual detection of clostridium perfringens alpha toxin according to claim 2, wherein said prokaryotic expression CPA protein truncation CPANThe construction and the preparation of the antibody comprise the following steps:
(1) CPA protein truncation CPANThe construction of (1): because the CPA protein has toxicity and lethality, in order to facilitate the subsequent antiserum preparation, the CPA mutant is used to eliminate the toxic influence on the immune animals in the experiment; plasmid containing mutant of amino acid at position 4 (pET30 a-CPA) given by professor of the aged cloudm4) And a C-terminal triple-copy tandem plasmid (pET30 a-CPA)C3) (ii) a At CPAm4Design of primers (CPA)m4Del TM-F, SEQ ID No.2 and CPAm4Dele TM-R, SEQ ID No.3) deletion transmembrane domain to obtain N-terminal truncated plasmid pET30a-CPANThe plasmid contains only two amino acid mutations (D56G, D130G);
(2) preparing an antibody: the constructed pET30a-CPANAnd pET30a-CPA for benefit of professorC3Transforming escherichia coli BL21(DE3) competent cells by the prokaryotic expression vector, and inducing and purifying recombinant protein by IPTG; anti-CPA was obtained by immunizing rabbits three times with a protein amount of 1mg/mLC3And CPANPurifying the polyclonal antibody by a rabbit serum and Saturated Ammonium Sulfate (SAS) precipitation method, and detecting the titer of the antibody by Western-blot and ELISA;
(3) CPA Using semi-permeable Membrane methodNLabeling Fluorescein Isothiocyanate (FITC) of the antibody so as to facilitate the coupling and fluorescence detection of the subsequent silica microspheres, and detecting the fluorescence intensity of the microspheres through a fluorescence microscope by utilizing the double-antibody sandwich principle of combining antigen and antibody, namely the concentration of the corresponding clostridium alpha toxin.
4. The method for visual detection of clostridium perfringens alpha toxin according to claim 1, wherein said CPA protein truncation silica microsphere is coupled, comprising the steps of:
(1) the toxicity substitution experiment, namely the lecithin hydrolysis experiment, is used for quantifying the clostridium perfringens alpha toxin, and the finally measured natural CPA concentration is 10LD50;
(2) Activation of silica microspheres: CPA coupled with surface of carboxylated silicon dioxide microsphereNAdding a polyclonal antibody, namely adding coupling agents of N-hydroxysuccinimide (NHS) and carbodiimide (EDC) with the final concentration of 10mg/mL, and finally blocking;
(3) optimizing the conditions of the silica microsphere detection experiment: including optimally coupled CPAC3Antibody conditions, optimal blocking conditions, optimal coupling detection antibody conditions; finally, the optimal conditions for the fluorescence detection experiment were determined from the experimental data, i.e.capture antibody (CPA) at 0.1mg/ml at 25 ℃C3) After 2h interaction with activated silica microspheres, blocking was performed overnight at 4 ℃ with 5% BSA, and the final day at 37 ℃ with alpha toxin and 0.2mg/ml detection antibody (FITC-CPA)N) And (3) interacting with the silica microspheres coupled with the capture antibody for 1h, and detecting by a fluorescence microscope.
5. The method for visual detection of clostridium perfringens alpha toxin according to claim 1, wherein said alpha toxin capture standard curve is established with a detection line sensitivity of 0.625LD50The detection time is 90 min.
6. The method for visual detection of alpha toxin of clostridium perfringens according to claim 5 wherein said establishment of said alpha toxin capture standard curve comprises the steps of:
(1) establishment of a standard curve: carrying out double gradient dilution on the natural clostridium perfringens alpha toxin, wherein the dilution is 5, each dilution is 3 biological repetitions, and then detecting the fluorescence intensity of a silica microsphere coupled to the FITC labeled antibody to obtain a group of fluorescence pictures;
(2) performing gray value analysis on the fluorescence intensity in the picture, firstly converting the picture into an 8-bit gray image and eliminating background interference, then selecting brightness values in all image areas to perform averaging analysis, finally obtaining the average gray value of the corresponding image, and sorting data to obtain a regression equation Y which is 0.01915X +0.002875(R is the sum of R and R is the sum of X and R is the sum of Y and R is20.9972); wherein X represents LD50Y represents the mean gray value;
(3) programming an image processing technology into an intelligent mobile phone APP, firstly analyzing RGB values of a picture, then converting the RGB color values into hexadecimal color code gray, thereby obtaining the gray value of the picture, and finally utilizing an IF algorithm to enable different gray value ranges to correspond to CPA concentrations; after the APP is prepared, the corresponding CPA concentration can be directly obtained by uploading a fluorescence picture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883292.3A CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883292.3A CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111983240A true CN111983240A (en) | 2020-11-24 |
CN111983240B CN111983240B (en) | 2023-11-21 |
Family
ID=73441499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010883292.3A Active CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111983240B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050123563A1 (en) * | 2003-07-30 | 2005-06-09 | Doranz Benjamin J. | Lipoparticles comprising proteins, methods of making, and using the same |
CN103941004A (en) * | 2014-01-25 | 2014-07-23 | 山东农业大学 | Clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method |
US20160279213A1 (en) * | 2013-12-16 | 2016-09-29 | Merck Patent Gmbh | Survivin-Directed Cancer Vaccine Therapy |
CN107596361A (en) * | 2017-09-12 | 2018-01-19 | 浙江海隆生物科技有限公司 | Subunit vaccine of bovine A-type clostridium perfringens and preparation method and application thereof |
KR101823353B1 (en) * | 2016-09-02 | 2018-01-31 | 롯데푸드 주식회사 | Method for detecting rapidly botulium toxin A, B, E and Clostridium perfringens alpha toxin and detection kit |
CN108315451A (en) * | 2018-03-29 | 2018-07-24 | 河北出入境检验检疫局检验检疫技术中心 | Primer and probe for detecting C.perfringens and its application |
-
2020
- 2020-08-27 CN CN202010883292.3A patent/CN111983240B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050123563A1 (en) * | 2003-07-30 | 2005-06-09 | Doranz Benjamin J. | Lipoparticles comprising proteins, methods of making, and using the same |
US20160279213A1 (en) * | 2013-12-16 | 2016-09-29 | Merck Patent Gmbh | Survivin-Directed Cancer Vaccine Therapy |
CN103941004A (en) * | 2014-01-25 | 2014-07-23 | 山东农业大学 | Clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method |
KR101823353B1 (en) * | 2016-09-02 | 2018-01-31 | 롯데푸드 주식회사 | Method for detecting rapidly botulium toxin A, B, E and Clostridium perfringens alpha toxin and detection kit |
CN107596361A (en) * | 2017-09-12 | 2018-01-19 | 浙江海隆生物科技有限公司 | Subunit vaccine of bovine A-type clostridium perfringens and preparation method and application thereof |
CN108315451A (en) * | 2018-03-29 | 2018-07-24 | 河北出入境检验检疫局检验检疫技术中心 | Primer and probe for detecting C.perfringens and its application |
Non-Patent Citations (3)
Title |
---|
SHREYA DAS ET AL.: "A sandwich duplex immuno PCR for rapid and sensitive identification of Clostridium perfringens alpha and enterotoxin", 《ANAEROBE》 * |
杜吉革;王磊;薛麒;朱真;李启红;印春生;姚文生;康凯;陈小云;: "产气荚膜梭菌α毒素C末端的二拷贝串联表达与免疫原性分析", 中国兽医杂志, no. 01 * |
王艳, 刘士良, 郝冬梅, 庄宝珠, 张学, 傅宝玉: "聚合酶链式反应-单链构象多态性分析法检测大肠腺瘤及大肠癌APC基因突变", 中华肿瘤杂志, no. 04 * |
Also Published As
Publication number | Publication date |
---|---|
CN111983240B (en) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105906714B (en) | A kind of preparation and application of brucellosis specific fusion protein antigen | |
CN103497252A (en) | Single-domain heavy chain antibody L5-78 for Listeria monocytogenes | |
CN106290918A (en) | A kind of ELISA kit detecting antibodies toward salmonella | |
CN102731615A (en) | Detection reagent and detection method for PRRSV | |
CN108267582A (en) | Infection of Toxoplasma Gondii colloidal gold immuno-chromatography test paper strip and preparation method thereof | |
CN110133284A (en) | Proteantigen and its encoding gene and they identifying the application in mycoplasma hyopneumoniae inactivated vaccine antibody and natural infection antibody | |
CN112574320B (en) | Fusion protein antigen for diagnosing brucellosis of dog | |
CN109053883B (en) | Binding protein of NS1 protein | |
CN105061602B (en) | For detecting fusion protein, the preparation method and application of anti-pig enterotoxigenic escherichia coil antibody | |
CN109239341B (en) | Indirect ELISA kit for detecting bovine haemolytic mannheimia antibody and application thereof | |
CN110483625A (en) | A kind of Mycoplasma bovis imagination albumen MbovP732 and its application | |
CN109748971A (en) | A kind of ELISA antibody assay kit of duck tembusu virus and its application | |
CN111596070B (en) | Application of portunus trituberculatus tropomyosin allergy detection reagent | |
CN103235121A (en) | Indirect ELISA kit for detecting porcine transfusion transmitted virus 2 (TTV2) antibody | |
CN101367870A (en) | Bovine rotavirus recombinant VP6 protein antigen and method of preparing the same | |
CN107664694B (en) | A kind of ELISA kit based on E2 Protein Detection pig atypia pestivirus antibody | |
CN111983240B (en) | Visual detection method for clostridium perfringens alpha toxin | |
CN109342711B (en) | The ELISA kit of several species IL-1Ra and IL-1 β and its ratio Simultaneous Determination | |
CN110376388A (en) | A kind of haemophilus parasuis antibody detection method and its kit | |
CN114933639B (en) | African swine fever virus p72N epitope protein and preparation method and application thereof | |
CN108982847A (en) | A kind of indirect ELISA detection method for the duck reovirus leading to duck spleen necrosis | |
CN105037555B (en) | Conjugate and its preparation method and application | |
CN114409743A (en) | African swine fever virus p54 protein epitope and application thereof | |
CN107085103A (en) | A kind of antibodies toward salmonella latex agglutination detection method | |
CN109851662B (en) | Foot-and-mouth disease virus recombinant protein and related biological material and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |